NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

Target Audience

This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Hematopoietic Growth Factors
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Hematopoietic Growth Factors
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
01/10/2020
Course expires: 
01/10/2021
Cost:
$0.00

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Pamela Sue Becker, MD, PhD, Panel Chair, has disclosed that she has received grant/research support from AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, GlycoMimetics, Inc., Novartis Pharmaceuticals Corporation, Invivoscribe, Inc., Trovagene, and Pfizer Inc.; is a scientific advisor for Caremark/Accordant Health Services; receives consulting fees from Gerson Lehrman Group; and has equity interest/stock options in Secura Bio.
Elizabeth A. Griffiths, MD, Panel Vice Chair, has disclosed that she is a scientific advisor for AbbVie, Inc., Alexion Pharmaceuticals, Inc., Boston Biomedical, Celgene Corporation, Partner Therapeutics, and Persimmune; receives honoraria from AbbVie, Inc., Boston Biomedical, and Novartis Pharmaceuticals Corporation; receives grant/research support from Astex Pharmaceuticals and Genentech, Inc.; and receives a consulting fee from Celgene Corporation and Partner Therapeutics.
Laura M. Alwan, PharmD, BCOP, Panel Member, has disclosed that she has received honoraria from Clinical Care Outcomes and Pharmacy Times Continuing Education.
Gary H. Lyman, MD, MPH, FRCP, Panel Member, has disclosed that he receives consulting fees from Agendia BV, Amgen Inc., Genomic Health, Inc., Halozyme, Inc., Mylan, Partners Healthcare, Samsung Bioepis, Pfizer Inc., and Spectrum Pharmaceuticals, Inc.
Lia E. Perez, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Jennifer Burns, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Jennifer Keller, MSS, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships.
Lenora A. Pluchino, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

To view all of the conflicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-20-002-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 10, 2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing